Examining anticoagulation in pregnant women using Lovenox three times a day
Anticoagulation Profile in Pregnant Women Treated With Three Times a Day of Low Molecular Weight Heparin (LMWH)
This study tests if giving pregnant women Lovenox three times a day helps keep their blood thinner and safer from clots compared to the usual twice-daily dose.
Quick facts
| Phase | Phase 4 |
|---|---|
| Study type | Interventional |
| Enrollment | 12 (estimated) |
| Ages | 18 Years and up |
| Sex | Female |
| Sponsor | University of California, Irvine Academic / other |
| Locations | 1 site (Orange, California) |
| Trial ID | NCT04861103 on ClinicalTrials.gov |
What this trial studies
This study investigates the anticoagulation profile of pregnant women who are treated with low molecular weight heparin (Lovenox) administered three times a day. Given the increased risk of blood clots during pregnancy, the study aims to determine if more frequent dosing can achieve adequate medication levels throughout the day. The research focuses on women who require therapeutic doses of Lovenox and evaluates the effectiveness of this dosing strategy compared to traditional twice-daily dosing. The study is conducted at the University of California, Irvine.
Who should consider this trial
Good fit: Ideal candidates are nulliparous or multiparous women aged 18 or older with a single intrauterine pregnancy requiring therapeutic low molecular weight heparin.
Not a fit: Patients who are pregnant with multiples, under 18 years old, have a history of Heparin Induced Thrombocytopenia, or are allergic to enoxaparin may not benefit from this study.
Why it matters
Potential benefit: If successful, this approach could significantly reduce the risk of blood clots in pregnant women by ensuring more consistent anticoagulation levels.
How similar studies have performed: While there is limited data on this specific dosing strategy, previous studies indicate that many patients do not achieve adequate anticoagulation levels with current dosing recommendations, suggesting a need for further investigation.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Nulliparous or multiparous women with single intrauterine pregnancies who require therapeutic low molecular weight heparin during their pregnancy. * Participants must be age 18 or older. Exclusion Criteria: * Women with multiples. * Women less than age 18 * History of Heparin Induced Thrombocytopenia (HIT) * Allergy to enoxaparin
Where this trial is running
Orange, California
- University of California Irvine — Orange, California, United States (Recruiting)
Study contacts
- Principal investigator: Afshan Hameed — University of California, Irvine
- Study coordinator: Lizette Spears
- Email: lspiers@hs.uci.edu
- Phone: 714.456.5694
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.